AGIO experienced a massive $1.09 billion swing from profit to loss despite doubling revenue, indicating significant one-time charges or writedowns that weren't present in the prior year.
The dramatic reversal from $673.7M profit to $412.8M loss represents a staggering financial deterioration that likely stems from major one-time events, asset impairments, or accounting adjustments rather than operational performance given the strong revenue growth. This volatility suggests significant underlying business changes that investors need to investigate further, particularly given the company's dependence on clinical-stage products and recent FDA approvals.
AGIO's financials show a paradoxical pattern with revenue doubling to $30M and modest increases in operating expenses (R&D up 12.7%, SG&A up 15%), yet the company swung from $674M profit to $413M loss—a $1.09B deterioration. The balance sheet contracted significantly with total assets falling 22% to $1.3B and stockholders' equity dropping 22.6% to $1.2B, while cash actually improved and liabilities decreased, suggesting major non-cash charges or asset writedowns drove the massive loss. This represents an extraordinary financial transformation that requires immediate investigation into the underlying causes.
Net income declined 161.3% — review whether driven by operations, interest costs, or non-recurring items.
Capital expenditure jumped 156.1% — major investment cycle underway; assess returns on deployment.
Strong top-line growth of 97.5% — accelerating demand or successful expansion into new markets.
Equity decreased 22.6% — buybacks or losses reducing book value, monitor solvency ratios.
Total assets contracted 22% — asset sales, write-downs, or balance sheet optimization underway.
Inventory built 19.2% — monitor whether demand supports this build or if write-downs may follow.
Cash grew 16.9% — improving liquidity position supports investment and shareholder returns.
SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.
Liabilities reduced 14.8% — deleveraging improves balance sheet strength and financial flexibility.
R&D investment increased 12.7% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →